TaiRx, Inc.
TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company's products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various … Read more
TaiRx, Inc. (6580) - Total Liabilities
Latest total liabilities as of June 2025: NT$32.07 Million TWD
Based on the latest financial reports, TaiRx, Inc. (6580) has total liabilities worth NT$32.07 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
TaiRx, Inc. - Total Liabilities Trend (2019–2024)
This chart illustrates how TaiRx, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
TaiRx, Inc. Competitors by Total Liabilities
The table below lists competitors of TaiRx, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eimco Elecon (India) Limited
NSE:EIMCOELECO
|
India | ₹507.07 Million |
|
ITM Semiconductor Co. Ltd
KQ:084850
|
Korea | ₩423.89 Billion |
|
Data Image Corporation
TW:3168
|
Taiwan | NT$1.11 Billion |
|
Mostostal Zabrze - Holding SA
WAR:MSZ
|
Poland | zł679.20 Million |
|
Tze Shin International Co Ltd
TW:2611
|
Taiwan | NT$1.27 Billion |
|
209640
KQ:209640
|
Korea | ₩37.44 Billion |
|
Nanoform Finland Plc
HE:NANOFH
|
Finland | €12.56 Million |
|
ONEJOON Co. Ltd.
KQ:382840
|
Korea | ₩68.98 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down TaiRx, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 20.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TaiRx, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TaiRx, Inc. (2019–2024)
The table below shows the annual total liabilities of TaiRx, Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$36.27 Million | -40.17% |
| 2023-12-31 | NT$60.62 Million | +10.38% |
| 2022-12-31 | NT$54.92 Million | +78.55% |
| 2021-12-31 | NT$30.76 Million | -21.83% |
| 2020-12-31 | NT$39.35 Million | +23.89% |
| 2019-12-31 | NT$31.76 Million | -- |